Sichuan Kelun Pharmaceutical (002422) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 was ¥4.19 billion, down 15.48% year-over-year; net profit attributable to shareholders was ¥200 million, a 70.18% decrease year-over-year.

• Year-to-date revenue reached ¥13.28 billion, down 20.92% from the same period last year; net profit attributable to shareholders was ¥1.20 billion, down 51.41%.

• The report was not audited.

Financial highlights

• Q3 basic and diluted EPS were ¥0.12, down 71.43% year-over-year; year-to-date EPS was ¥0.75, down 52.23%.

• Operating cash flow for Q3 was ¥1.68 billion, down 48.57% year-over-year.

• Total assets at quarter-end were ¥40.10 billion, up 7.47% from year-end 2024.

• Shareholders’ equity was ¥23.71 billion, up 5.46% from year-end 2024.

Outlook and guidance

• No explicit forward-looking guidance provided, but significant product approvals and R&D progress were highlighted.